WHO has announced it will update treatment guidelines for multidrug-resistant TB, following strong results of MSF's TB PRACTECAL trial. But the price of the new regimens must come down.
A new all-oral six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care, according to results announced at the 52nd Union World Conference on Lung Health.